PATENT CLAIM ANALYSIS

Application Number: 16079059
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to methods of treating, preventing or managing intestinal fibrosis by inhibiting SMAD7. The invention is also directed to methods of monitoring effectiveness of treatment or management of intestinal fibrosis using a SMAD7 antisense oligonucleotide, as well as methods of regulating SMAD7 antisense oligonucleotide treatment, based on analysis of Transforming Growth Factor-β (TGF-β) levels, α-Smooth Muscle Actin (a-SMA) levels, and/or phosphorylated Mothers Against Decapentaplegic Homolog 3 (p-SMAD3) levels.

Claim (Index 131):
The method of  claim 129  or  130 , wherein, if the level of \u03b1-SMA is at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, or at least 70% decreased after said administration step compared to the level of \u03b1-SMA before said administration step, then administering to the patient a subsequent dose that is the same as the initial dose or smaller than the initial dose.

Metadata:
- Claim Count in Document: 51.0
- Percentile: 96.0
- Lexical Diversity: 1.55556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15063077', '16046389', '12854558', '14144029', '12264058']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7754976799834707
- 35 USC 102 Novelty (BERT): 0.5388797842198177
- Combined Prediction Score: 0.7518358904071055
- Mean Citation Score: 335.939554
- Max Citation Score: 336.40283
- Similarity Product: 161.87786711824683

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test